K2 Therapeutics

K2 Therapeutics is a biotechnology company focused on the discovery and development of antibody-based therapies for challenging multi-pass membrane protein targets. Founded in 2023, the company leverages its proprietary synthetic biology and directed evolution platforms to generate and optimize antibodies. The co-founders include President and CEO Joshua A. Salafsky, Chief Scientific Officer Justin Farlow, and Senior Vice President of Drug Discovery Sheila Dewitt. The founding team brings together extensive experience from companies like Synthekine, Novo Nordisk, and Amgen, with backgrounds in biophysics, protein engineering, and drug discovery.

The company's core technology enables the discovery of antibodies against complex targets that are often difficult to address with conventional methods. This approach has the potential to unlock new therapeutic options for a variety of diseases. K2 Therapeutics operates in the biopharmaceutical market, aiming to develop its own pipeline of innovative therapies. In May 2024, the company announced it had secured $55 million in a Series A financing round. The round was co-led by Westlake Village BioPartners, OrbiMed, and Nextech, with participation from Vida Ventures. These funds are intended to advance the company's platform and propel its therapeutic programs toward clinical development.

Keywords: antibody discovery, therapeutics, biotechnology, membrane proteins, drug discovery, synthetic biology, directed evolution, biopharmaceutical, Series A, oncology